Cannabis
Conditions
Brief summary
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Detailed description
To characterize the acute effects of oral Dronabinol (10 mg capsule) in women relative to men and to begin probing the mechanisms that may underlie gender differences.
Interventions
DRUGPlacebo
Placebo pill (no active cannabinoids)
DRUGDronabinol
10 mg capsule of Dronabinol will be administered orally.
Sponsors
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* At least one lifetime exposure to cannabis * Good physical and mental health
Exclusion criteria
* Cannabis naive individuals * Major current or recent stressors * Taking estrogen supplements or oral contraceptive pills (for women) * Sesame oil allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS) | changes in high assessed over the following timepoints: baseline, +60, +80, +120, +180, +300 minutes after start of oral Dronabinol administration. | Subjective measure of THC induced high |
| Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT) | baseline and +80 minutes after start of oral Dronabinol administration. | Measured as delay recall on the AVLT |
Countries
United States
Contacts
Primary ContactCarly Hewes, BS
Outcome results
None listed